{"uri": "eng-9410698", "concepts": [{"uri": "http://en.wikipedia.org/wiki/Autoimmune_disease", "type": "wiki", "score": 100, "label": {"eng": "Autoimmune disease"}}, {"uri": "http://en.wikipedia.org/wiki/Food_and_Drug_Administration", "type": "wiki", "score": 90, "label": {"eng": "Food and Drug Administration"}}, {"uri": "http://en.wikipedia.org/wiki/Systemic_scleroderma", "type": "wiki", "score": 87, "label": {"eng": "Systemic scleroderma"}}, {"uri": "http://en.wikipedia.org/wiki/T_cell", "type": "wiki", "score": 85, "label": {"eng": "T cell"}}, {"uri": "http://en.wikipedia.org/wiki/Orphan_drug", "type": "wiki", "score": 81, "label": {"eng": "Orphan drug"}}, {"uri": "http://en.wikipedia.org/wiki/Clinical_trial", "type": "wiki", "score": 73, "label": {"eng": "Clinical trial"}}, {"uri": "http://en.wikipedia.org/wiki/B_cell", "type": "wiki", "score": 70, "label": {"eng": "B cell"}}, {"uri": "http://en.wikipedia.org/wiki/Biotechnology", "type": "wiki", "score": 59, "label": {"eng": "Biotechnology"}}, {"uri": "http://en.wikipedia.org/wiki/Organ_(biology)", "type": "wiki", "score": 54, "label": {"eng": "Organ (biology)"}}, {"uri": "http://en.wikipedia.org/wiki/Skin", "type": "wiki", "score": 48, "label": {"eng": "Skin"}}, {"uri": "http://en.wikipedia.org/wiki/Cohort_study", "type": "wiki", "score": 44, "label": {"eng": "Cohort study"}}, {"uri": "http://en.wikipedia.org/wiki/Cell_therapy", "type": "wiki", "score": 43, "label": {"eng": "Cell therapy"}}, {"uri": "http://en.wikipedia.org/wiki/Fibrosis", "type": "wiki", "score": 39, "label": {"eng": "Fibrosis"}}, {"uri": "http://en.wikipedia.org/wiki/Rare_disease", "type": "wiki", "score": 34, "label": {"eng": "Rare disease"}}, {"uri": "http://en.wikipedia.org/wiki/Diagnosis", "type": "wiki", "score": 31, "label": {"eng": "Diagnosis"}}, {"uri": "http://en.wikipedia.org/wiki/Doctor_of_Medicine", "type": "wiki", "score": 30, "label": {"eng": "Doctor of Medicine"}}, {"uri": "http://en.wikipedia.org/wiki/Immune_system", "type": "wiki", "score": 30, "label": {"eng": "Immune system"}}, {"uri": "http://en.wikipedia.org/wiki/Nasdaq", "type": "wiki", "score": 28, "label": {"eng": "Nasdaq"}}, {"uri": "http://en.wikipedia.org/wiki/Lupus", "type": "wiki", "score": 27, "label": {"eng": "Lupus"}}, {"uri": "http://en.wikipedia.org/wiki/Myositis", "type": "wiki", "score": 27, "label": {"eng": "Myositis"}}, {"uri": "http://en.wikipedia.org/wiki/United_States", "type": "loc", "score": 22, "label": {"eng": "United States"}, "location": {"type": "country", "label": {"eng": "United States"}}}, {"uri": "http://en.wikipedia.org/wiki/Philadelphia", "type": "loc", "score": 17, "label": {"eng": "Philadelphia"}, "location": {"type": "place", "label": {"eng": "Philadelphia"}, "country": {"type": "country", "label": {"eng": "United States"}}}}], "eventDate": "2024-03-20", "totalArticleCount": 9, "title": {"eng": "Cabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash Runway"}, "summary": {"eng": "On March 21, 2024, Cabaletta Bio Inc (NASDAQ:CABA) released its 8-K filing, detailing the fourth quarter and full year financial results for 2023. The clinical-stage biotechnology company, which specializes in engineered T cell therapies for autoimmune diseases, reported a net loss of $20.886 million or $0.46 per share, which is in line with analyst expectations of a $0.4374 loss per share. Despite the net loss, the company's financial position remains strong, with cash, cash equivalents, and sho"}, "location": null, "categories": [{"uri": "dmoz/Health/Conditions_and_Diseases/Cancer", "label": "dmoz/Health/Conditions and Diseases/Cancer", "wgt": 100}, {"uri": "dmoz/Health/Women's_Health/Conditions_and_Diseases", "label": "dmoz/Health/Women's Health/Conditions and Diseases", "wgt": 100}, {"uri": "dmoz/Health/Men's_Health/Conditions_and_Diseases", "label": "dmoz/Health/Men's Health/Conditions and Diseases", "wgt": 100}, {"uri": "news/Business", "label": "news/Business", "wgt": 79}], "articleCounts": {"eng": 9}, "sentiment": 0.1450980392156862, "wgt": 448588800, "relevance": 1}